Exelixis Inc
EXEL38.013USD
+0.582+1.56%
Horário de mercado （ET）Cotações atrasadas em 15 min
10.71BValor de mercado
20.54P/L TTM
Mais detalhes de Exelixis Inc Empresa
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Informações da empresa
Código da empresaEXEL
Nome da EmpresaExelixis Inc
Data de listagemApr 11, 2000
Fundado em1994
CEODr. Michael M. Morrissey, Ph.D.
Número de funcionários1147
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 11
Endereço1851 Harbor Bay Parkway
CidadeALAMEDA
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94502
Telefone16508377000
Sitehttps://www.exelixis.com/
Código da empresaEXEL
Data de listagemApr 11, 2000
Fundado em1994
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.37M
+33.08%
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
1.26M
+0.15%
Mr. Jeffrey J. Hessekiel, J.D.
Mr. Jeffrey J. Hessekiel, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
469.73K
+48.81%
Dr. Dana T. Aftab, Ph.D.
Dr. Dana T. Aftab, Ph.D.
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
391.52K
+51.34%
Mr. Patrick Joseph Haley
Mr. Patrick Joseph Haley
Executive Vice President - Commercial
Executive Vice President - Commercial
347.62K
+75.36%
Mr. Jack L. Wyszomierski
Mr. Jack L. Wyszomierski
Independent Director
Independent Director
337.77K
+2.73%
Dr. Amy C. Peterson, M.D.
Dr. Amy C. Peterson, M.D.
Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
192.16K
+486.28%
Dr. George H. Poste, Ph.D.
Dr. George H. Poste, Ph.D.
Independent Director
Independent Director
150.18K
+1.27%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
72.17K
+2.67%
Ms. Julie Anne Smith
Ms. Julie Anne Smith
Independent Director
Independent Director
763.00
-92.92%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.37M
+33.08%
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
1.26M
+0.15%
Mr. Jeffrey J. Hessekiel, J.D.
Mr. Jeffrey J. Hessekiel, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
469.73K
+48.81%
Dr. Dana T. Aftab, Ph.D.
Dr. Dana T. Aftab, Ph.D.
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
391.52K
+51.34%
Mr. Patrick Joseph Haley
Mr. Patrick Joseph Haley
Executive Vice President - Commercial
Executive Vice President - Commercial
347.62K
+75.36%
Mr. Jack L. Wyszomierski
Mr. Jack L. Wyszomierski
Independent Director
Independent Director
337.77K
+2.73%
Detalhamento da receita
Moeda: USDTempo de atualização: dom, 6 de abr
Moeda: USDTempo de atualização: dom, 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por EmpresaUSD
Nome
Receita
Proporção
CABOMETYX
1.80B
82.92%
License revenues
349.24M
16.10%
COMETRIQ
11.16M
0.51%
Collaboration services revenues
10.06M
0.46%
Por RegiãoUSD
Nome
Receita
Proporção
U.S
1.82B
84.06%
Europe
318.63M
14.69%
Japan
27.08M
1.25%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
CABOMETYX
1.80B
82.92%
License revenues
349.24M
16.10%
COMETRIQ
11.16M
0.51%
Collaboration services revenues
10.06M
0.46%
Acionista
Tempo de atualização: sex, 21 de fev
Tempo de atualização: sex, 21 de fev
Estatísticas dos acionistas
Tipo
Estatísticas dos acionistas
Acionista
Proporção
The Vanguard Group, Inc.
10.66%
BlackRock Institutional Trust Company, N.A.
9.69%
Farallon Capital Management, L.L.C.
8.51%
Renaissance Technologies LLC
5.55%
State Street Global Advisors (US)
4.14%
Other
61.45%
Estatísticas dos acionistas
Acionista
Proporção
The Vanguard Group, Inc.
10.66%
BlackRock Institutional Trust Company, N.A.
9.69%
Farallon Capital Management, L.L.C.
8.51%
Renaissance Technologies LLC
5.55%
State Street Global Advisors (US)
4.14%
Other
61.45%
Tipo
Acionista
Proporção
Investment Advisor/Hedge Fund
35.97%
Investment Advisor
33.06%
Hedge Fund
18.79%
Pension Fund
2.95%
Individual Investor
2.28%
Research Firm
1.77%
Sovereign Wealth Fund
1.22%
Bank and Trust
0.48%
Family Office
0.10%
Other
3.38%
Participação acionária institucional
Tempo de atualização: seg, 20 de jan
Tempo de atualização: seg, 20 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
972
265.48M
94.85%
-6.82M
2024Q4
992
262.76M
93.66%
-11.36M
2024Q3
924
259.58M
90.96%
-10.18M
2024Q2
908
255.61M
87.75%
-22.29M
2024Q1
905
264.69M
87.26%
-20.82M
2023Q4
882
270.85M
87.07%
-16.64M
2023Q3
847
278.02M
87.32%
-18.15M
2023Q2
833
285.95M
87.85%
-21.34M
2023Q1
841
294.75M
90.97%
-14.08M
2022Q4
839
295.50M
91.62%
-5.46M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
29.37M
10.49%
+120.47K
+0.41%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
26.71M
9.54%
-308.83K
-1.14%
Dec 31, 2024
Farallon Capital Management, L.L.C.
23.44M
8.37%
--
--
Mar 05, 2025
Renaissance Technologies LLC
15.30M
5.47%
-64.05K
-0.42%
Dec 31, 2024
State Street Global Advisors (US)
11.41M
4.08%
-31.73K
-0.28%
Dec 31, 2024
LSV Asset Management
8.17M
2.92%
+67.47K
+0.83%
Dec 31, 2024
Fuller & Thaler Asset Management Inc.
7.63M
2.73%
+708.31K
+10.23%
Dec 31, 2024
Geode Capital Management, L.L.C.
5.16M
1.84%
-5.12K
-0.10%
Dec 31, 2024
Dimensional Fund Advisors, L.P.
5.10M
1.82%
-153.57K
-2.92%
Dec 31, 2024
AQR Capital Management, LLC
3.97M
1.42%
+810.86K
+25.69%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Tempo de atualização: dom, 6 de abr
Tempo de atualização: dom, 6 de abr
Nome
Proporção
iShares Genomics Immunology and Healthcare ETF
4.81%
Tema Oncology ETF
4.2%
Alger Russell Innovation ETF
3.77%
First Trust NYSE Arca Biotechnology Index Fund
3.34%
Burney US Factor Rotation ETF
3.31%
Invesco Biotechnology & Genome ETF
2.89%
ERShares Entrepreneurs ETF
2.66%
First Trust Health Care Alphadex Fund
2.51%
Range Cancer Immunotherapy ETF
2.48%
Adaptiv Select ETF
2.04%
Ver Mais
iShares Genomics Immunology and Healthcare ETF
Proporção4.81%
Tema Oncology ETF
Proporção4.2%
Alger Russell Innovation ETF
Proporção3.77%
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.34%
Burney US Factor Rotation ETF
Proporção3.31%
Invesco Biotechnology & Genome ETF
Proporção2.89%
ERShares Entrepreneurs ETF
Proporção2.66%
First Trust Health Care Alphadex Fund
Proporção2.51%
Range Cancer Immunotherapy ETF
Proporção2.48%
Adaptiv Select ETF
Proporção2.04%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados